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Summary The radiosensitizing and cytotoxic properties of the drug RSU-1069, (l-(2-nitro-l-imidazolyl)-3-(l-
aziridino)-2-propanol) a 2-nitroimidazole with an aziridine ring in its side-chain, have been examined both in
vivo and in vitro. Studies with the KHT Sarcoma or RIFI tumour indicated that, at doses between 0.04 and
0.16mg g-1 body wt, the drug was increasingly effective at killing tumour cells when combined with
radiation. Cell survival in both tumours following combined RSU-1069 and radiation (1500 or 2000cGy)
treatment was similar when the drug was given 60min before or immediately after irradiation suggesting that
the effect observed was due to hypoxic cell cytotoxicity rather than radiosensitization.
Studies with CHO cells in vitro indicated that RSU-1069 was equally as effective as a number of other 2-
nitroimidazoles as a radiosensitizer when drug exposure and radiation treatment was given at 4°C. It was
substantially more toxic to hypoxic than to aerobic CHO cells (a factor of 90 in dose to give equivalent cell
killing) and was much more toxic to CHO cells than misonidazole (a factor of - 100 in dose) at 37°C. HeLa
cells were more sensitive to RSU-1069 than CHO cells and, under hypoxic conditions, were -20-fold more
sensitive to the drug than when aerobic.
Prior incubation of hypoxic CHO cells with RSU-1069 at toxic concentrations did not influence the
sensitivity of the surviving cells to radiation treatment (i.e. there was no shoulder removal as is observed with
misonidazole) nor did prior radiation treatment influence the sensitivity of the surviving cells to drug
treatment.
Overall the results indicate that RSU-1069 is a highly effective cytotoxic agent for hypoxic cells both in vivo
and in vitro but, when drug exposure and radiation treatment are given at 4°C, it is not a more effective
sensitizer than other 2-nitroimidazoles.
Research over the last 10-15 years has demon-
strated that many compounds containing nitro
groups can act as radiation sensitizers of hypoxic
cells. It has been found that nitroimidazoles, and
particularly 2-nitroimidazoles, act as specific
sensitizers of hypoxic cells in vivo in animal tumour
models. It has also been demonstrated that these
compounds have a differential toxicity for hypoxic
cells both in vivo and in vitro. These properties
have resulted in the use of some of these com-
pounds in clinical studies as adjuvants to radiation
therapy. Most of the clinical trials have been
carried out with the drug misonidazole but these
have been limited by toxicity which has prevented
more than minimally effective doses of the drug
from being administered to patients undergoing
radiotherapy (Dische, 1985). This limitation has led
to a search for drugs which are either less toxic or
more effective sensitizers and initial clinical studies
are underway with two drugs, SR 2508 and RO-03-
8799, which human studies have shown are less
toxic at effective concentrations.
Recent experimental studies (Adams et al.,
1984a,b) have suggested that another drug RSU-
1069, a 2-nitroimidazole which has an aziridine ring
in its side-chain is a much more effective sensitizer
than misonidazole both in vitro and in vivo. The
studies reported in this paper were designed to
examine the hypoxic cell sensitizing ability and
hypoxic cell cytotoxicity of this drug both in vitro
and in vivo. The results indicate that the drug is
indeed more effective on a molar basis than
misonidazole when combined with radiation but
that this is due to a greater degree of hypoxic cell
cytotoxicity and not to enhanced radiosensitizing
ability.
Materials and methods
In vivo studies
The KHT sarcoma (Kallman et al., 1967) and the
RIFI tumour (Twentyman et al., 1980) used in
these studies were grown in 10-14wk old C3H/Jax
male mice. The KHT sarcomas were transplanted
s.c. in both flanks and treated when they reached a
diameter of cm, while the RIF1 tumours were
transplanted i.m. into the left hind leg and treated
when they reached a size of -0.8g (determined by
measuring the leg diameter and converting this to
tumour weight using a previously determined
calibration curve). Irradiation was given to the
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whole-body using a double-headed 137Cs y-ray unit
(Cunningham et al., 1965) at a dose-rate of
68cGymin-1. The RSU-1069 was dissolved in PBS
and injected i.p. in a volume of 0.025mlg-1 body
wt. It was given either 60min before the start of the
irradiation or immediately after the irradiation was
completed, except in two experiments when it was
split into 5 equal doses which were given at hourly
intervals with the irradiation starting immediately
after the third injection.
The effect of the treatment on both tumours was
determined using a cell survival assay. The tumours
were excised from the animals either 3h after the
single drug injection or 1 h after the fifth of the
multiple injections and cell suspensions were
prepared from both tumours using a combined
mechanical and enzyme (trypsin+DNAase)
digestion procedure as described previously for the
KHT sarcoma (Thomson & Rauth, 1974) with the
following modifications. The RIFI tumours were
not forced through a stainless-steel screen before
being treated with the enzymes. Incubation was in
PBS at 37°C in a roller wheel for 30-40min with
0.2% trypsin (Difco bactotrypsin) and DNAse I
(Sigma-250 Kunitz unitsml- 1). After the enzyme
treatment all resuspensions and dilutions were done
in a-minimal essential medium (a-MEM) containing
10% (KHT) or 15% (RIFI) foetal calf serum
(FCS). These procedures yielded suspensions of
single cells which were >95% viable (excluded
trypan-blue) with 5-1Ox 107KHT cellsg- or 2-
4x 107 RIFI cellsg-1. The survival of the KHT
cells was determined using a lung colony assay (Hill
& Bush, 1969) and that of the RIFI cells
determined by plating in vitro. The KHT cells were
injected i.v. into C3H/Jax male mice admixed with
2 x 106 heavily irradiated (100Gy) KHT cells plus
106 plastic microspheres (15pm diameter 3M. Co.
Ltd., Minneapolis, USA) and the number of lung
colonies formed 18-21 days later was determined.
The RIFI cells were plated at multiple dilutions in
a-MEM plus 15% FCS and incubated for 9-11
days before the colonies were stained with
methylene blue (dissolved in 50% ethanol) and
counted.
In vitro studies
The CHO and HeLa cell lines used were
maintained in suspension culture and plated in a-
MEM supplemented with 10% v/v foetal calf
serum. (Flow Laboratories, Rockville, MD, USA).
When required, hypoxia was achieved by flowing
prehumidified nitrogen (1 1min-1) containing 5%
CO2 and <0.001% 02 (Liquid Carbonic Canada,
Ltd., Scarborough, Ontario, Canada) over 10ml
cell suspensions (2 x 106 cells ml-1) in a-MEM
medium contained in small glass vials maintained at
37°C. For cytotoxicity measurements, exposure to
the drug occurred under similar conditions and
exposure to nitrogen was simultaneous with the
mixing of cells and drug. In some experiments the
drug containing medium was gassed with N2
separately and then mixed with a previously gassed
cell suspension. Exposure to radiation was carried
out using a 60Co y-ray source at a dose rate of
200cGymin-'. Cells were exposed to the drug for
15 min (at 4°C) under hypoxic or aerobic conditions
before the start of irradiation.
Drug
The RSU-1069 was synthesized by Drs I. Ahmed
and T. Jenkins and obtained courtesy of Dr G.E.
Adams (Harwell, UK). Misonidazole (Ro 07-0582),
desmethyl misonidazole (Ro 05-9963), Ro 07-1902
and Ro 07-0913 were obtained courtesy of Dr C.
Smithen, Roche Products Ltd, Welwyn Garden
City, UK.
Results
The KHT sarcomas were irradiated with 2000cGy
either before or after administration of RSU-1069
and the cell survival determined is shown in the left
panel of Figure 1. Administration of the drug
resulted in a substantial reduction in cell survival
with no difference between the results obtained for
drug given before or after irradiation. To examine
prolonging the drug exposure, tumour-bearing
animals were given the same total drug dose as 5
equal injections at hourly intervals. The results
obtained were similar to those for a single dose as
indicated. In the upper part of the figure results for
drug treatment alone are given, indicating
significant toxicity particularly at high drug doses
(0.16mgg-1 or 750pmolkg-1). However the results
for the combination treatment indicate greater cell
killing due to the drug when combined with
radiation than are obtained with drug treatment
alone.
Also shown, for comparison, in the left panel of
Figure 1 are results obtained previously (Rauth et
al., 1978, 1980) for subcutaneously-growing KHT
sarcomas treated with misonidazole under similar
conditions. For irradiation following drug adminis-
tration, RSU-1069 is effective at doses 10-fold
lower than those used for misonidazole. This is
approximately in line with the difference in their
single dose lethal toxicity for mice - 0.15mgg-1 for
RSU-1069 vs. 1.8mgg-1 for misonidazole (Adams
et al., 1984a). However there is a clear difference in
the efficacy of misonidazole when given before or
after irradiation which is not evident for RSU-1069
and also there appears to be less cell killing when
misonidazole is given alone.CYTOTOXICITY OF RSU-1069 745
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Figure 1 Survival curves for KHT sarcomas (a) and RIFI tumours (b) treated with radiation and/or
different concentrations of RSU-1069. (a) Subcutaneously-growing KHT Sarcomas were treated with drug
alone (open symbols and upper solid line) or with drug given 1 h before (0) or immediately after (M) a
radiation dose of 2000cGy (lower solid line). In one experiment (,A) five equal drug doses were given
bracketting the radiation treatment. For comparison the broken lines with crosses indicate similar experiments
done previously using the drug misonidazole (Rauth et al., 1978, 1980). (b) RIFI tumours growing i.m. were
treated with drug alone (open symbols) or with drug given 1 h before (0) or immediately after (R) a
radiation dose of 1500cGy (solid line). The two broken lines in this part of the figure are the same as the
solid lines in part (a). All the lines in the figure were fitted to the data by eye.
The efficacy of RSU-1069 in combination with
irradiation was also examined in the RIFI tumour.
These experiments were similar to those with the
KHT sarcoma except that a dose of 1500cGy was
used. The results are shown in the right panel of
Figure 1. The RIFI tumour responded in an
identical manner to the KHT sarcoma with drug
given before or after irradiation giving similar
results. Drug treatment alone was also toxic for the
RIFI cells but again, when combined with
radiation, the extra cell killing attributable to drug
treatment was greater at the highest drug doses
used.
The results of Figure 1 suggest that in vivo RSU-
1069 is toxic to hypoxic cells at doses which are
> 10-fold less than those required for misonidazole.
To gain further insight into possible reasons for this
increased efficacy, a variety of in vitro experiments
using CHO or HeLa cells were carried out. The
first experiment determined the radiosensitizing
ability of RSU-1069 when hypoxic CHO cells were
exposed to the drug for 15min at 4°C prior to
irradiation. At this temperature drug metabolism
should be inhibited (there was no cytotoxicity for
drug treatment alone). The data of Figure 2
indicate that RSU-1069 does act as a sensitizer,
producing increasing sensitization of hypoxic cells
with increasing drug concentration.
Figure 3 compares the enhancement ratio for
hypoxic cells at 4°C as a function of drug
concentration for RSU-1069 and five other 2-
nitroimidazoles with similar electron affinity. The
data indicate that, as an electron-affinic sensitizer,
in the absence ofmetabolism, RSU-1069 is no moreRSU-1069
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Figure 2 Radiation survival curves for CHO cells exposed to RSU-1069 under hypoxic conditions at various
concentrations for 15min at 4°C prior to irradiation. Survival curves for aerobic and hypoxic cells are also
shown. The open circles and squares represent data obtained previously. The solid circles and squares were
obtained as controls in the current series ofexperiments.
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Figure 3a Radiation enhancement ratio as a function of drug concentration for CHO cells treated as in
Figure 2. Various symbols refer to the drugs whose structures are given in Figure 3b.
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efficient than other similar 2-nitroimidazoles. This
is in contrast to the results reported by Adams et
al. (1984a) who found that the drug was a more
efficient sensitizer than misonidazole, if cells were
exposed to the drug for 2h at room temperature
under hypoxic conditions, before irradiation. Under
such conditions drug metabolism might be affecting
the radiosensitizing properties of the drug.
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It has previously been reported (Wong et al.,
1978) that prolonged exposure of hypoxic cells to 2-
nitroimidazoles at 37°C followed by washing to
remove any free drug produces a radiosensitizing
effect which is characterized primarily by a
reduction in the shoulder of the radiation survival
curve. When hypoxic CHO cells were exposed to
various concentrations of RSU-1069 at 37°C for
3h, washed and then exposed to graded doses of
radiation under hypoxic conditions, the data in the
left panel of Figure 4 were obtained. It is apparent
that cell survival decreases with increasing drug
concentration and with increasing radiation dose.
However, if cell survival for each radiation dose
and each drug concentration is normalized to the
survival for exposure to drug alone (0cGy,N2) then
the right panel of Figure 4 indicates that, for
radiation doses between 1500 and 2500cGy and for
drug doses up to 1OJM, preincubation with the
drug has no effect on radiation survival even
though such a drug exposure results in marked
cytotoxicity when given alone. This is in contrast to
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Figure 4 Left side: Survival of CHO cells as a function of drug concentration and radiation dose for cells
exposed to the drug under hypoxic conditions for 3 h at 37°C, washed and then exposed to radiation under
hypoxic conditions. Right side: The data from the left panel normalized to remove the effect of toxicity due to
the drug alone in the absence of radiation (see text).
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results with misonidazole and desmethyl misoni-
dazole where reduction in the shoulder of the
radiation survival curve occurs at drug exposures
lower than that required for significant cytotoxicity.
Korbelik et al. (1981) reported that cells which
have been pre-irradiated show an enhanced
cytotoxic response to misonidazole exposure under
hypoxic conditions. Figure 5 presents survival data
for either irradiated (600cGy) or unirradiated CHO
cells exposed for varying lengths of time to various
drug concentrations under both aerobic and
hypoxic conditions. When corrections are made for
the killing due to radiation exposure alone (i.e. by
normalization to the curve labelled 0 cGy, N2 in
normalization to a control given only irradiation)
the data also indicate that pre-exposure to radiation
does not sensitize cells to subsequent exposure to
RSU-1069 under hypoxic conditions.
The data in Figures 1 to 5 are consistent with the
conclusion that the greater in vivo efficacy of RSU-
1069 is not due to it being a more effective
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radiosensitizer than misonidazole but arises rather
from increased hypoxic cell cytotoxicity. In
agreement with results obtained with other 2-nitro-
imidazoles, Figure 5 demonstrates that the toxicity
of RSU-1069 increases with drug concentration and
with duration of exposure and hypoxic cells are
very much more sensitive than aerobic cells. This
hypoxic cell cytotoxicity is further emphasized by
the data in Figure 6 which shows survival curves
for aerobic and hypoxic CHO cells exposed to
several 2-nitroimidazoles and for HeLa cells
exposed to RSU-1069 under aerobic and hypoxic
conditions. In contrast to the data of Figure 3
which show little if any effect of the imidazole side
chain on sensitizing ability, the data of Figure 6
indicate that for CHO cells hypoxic cell toxicity
increases in the sequence, misonidazole, azomycin
and RSU-1069, with dimethyl misonidazole similar
to or slightly more toxic that misonidazole. This
sequence appears to be maintained for aerobic
exposure. The ratios of drug concentrations
0
0 1 10 100
RSU 1069concentration (>M)
1000
J
10 000
Figure 5 Survival curves as a function of drug concentration for preirradiated and unirradiated CHO cells
exposed to RSU-1069 for various lengths of time under aerobic and hypoxic conditions. For exposure
conditions, see text.
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Figure 6 Survival curves as a function of drug concentration for CHO and HeLa cells exposed to a variety
of 2-nitroimidazoles under aerobic and hypoxic conditions for 3 h at 370C. For exposure conditions, see text.
Results for HeLa cells treated with misonidazole under hypoxic conditions are from Taylor & Rauth (1978).
required to reduce survival of CHO cells to ten
percent under aerobic vs. hypoxic conditions are
- 16, 8 and 90 for misonidazole, azomycin and
RSU-1069, respectively. In every situation where
comparison is possible, it would appear that HeLa
cells are more sensitive than CHO cells, perhaps
due to the increased ability of these cells to reduce
2-nitroimidazoles (Taylor & Rauth, 1978).
Discussion
The in vivo tumour results presented in Figure 1
indicate that RSU-1069 when combined with
radiation produces a far greater degree of cell kill
than either agent alone and that this effect is seen
with drug doses about a factor of ten lower than
are required with misonidazole. In contrast to
misonidazole the increased efficacy of the RSU-
1069 combined with radiation appears to be due to
a cytotoxic effect of RSU-1069 on the hypoxic cells
which survive the radiation treatment. Any radio-
sensitization which occurs would be masked by this
cytotoxic effect. This conclusion is supported by
several observations. First, the total cell kill in vivo
is independent of whether the drug is administered
60min before or immediately after irradiation. This
observation contrasts with data obtained for
misonidazole (Figure 1) where drug administration
following irradiation is much less effective than
administration before irradiation. Secondly, the in
vitro experiments (Figure 4) fail to show the
enhanced radiosensitization which is seen following
prolonged pre-exposure of hypoxic cells to other 2-
nitroimidazoles prior to irradiation. Thirdly, we
could not demonstrate an enhanced drug cyto-
toxicity in cells pre-exposed to radiation (Figure 5).
However, it must be pointed out that because of
the extreme cytotoxicity of the drug to hypoxic
cells it has not been possible to achieve drug
concentrations in vitro similar to those required
for misonidazole to demonstrate shoulder removal
from radiation survival curves or radiation-
sensitized cytotoxicity (Wong et al., 1978; Whitmore
& Gulyas, 1981).
Adams et al. (1984a) have published results
-
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indicating that doses of RSU-1069 similar to those
used in the present experiments can influence the
radiation response of MT tumours growing in
WHT mice. They interpreted their results as
indicating that RSU-1069 was acting as a
radiosensitizer but they only reported studies in
which the drug was given before irradiation thus
they could not have distinguished between radio-
sensitization and hypoxic cell toxicity. They did,
however, demonstrate that when the drug was given
3-5 h before irradiation it was much less effective
than when given 10-120min before irradiation. If it
is supposed that 3-5 h is sufficient in the MT
tumour for some of the hypoxic cells killed by the
drug to be replaced from the surviving aerobic cell
population, then their results are compatible with
those presented here and can be explained on the
basis of the cytotoxic action of the drug.
The combined observations of Adams et al.
(1984a) and ourselves suggest that, to achieve
maximum benefit from combining RSU-1069 with
radiation, the two agents should be given almost
simultaneously. The data of Figure 1 also indicate
that treatment with high doses of drug in the
absence of radiation produces a degree of cell
killing which implies that the drug is toxic to
aerobic cells within the tumour. Toxicity for
aerobic CHO and HeLa cells was also observed in
vitro (see Figure 6). However, at the highest drug
doses achieved in vivo the (presumably) hypoxic
cells which survive the initial dose of 1500 or
2000cGy have a survival level which is at least 10-
fold less than would be expected on the basis of
independent killing by the two agents. While this
again suggests the apparently greater sensitivity of
hypoxic cells to the cytotoxic effects of the drug,
the fact that the differences are less than those seen
for hypoxic vs. aerobic cells in vitro (Figures 5 and
6) may be indicative: (i) of a failure of the drug to
achieve uniform concentrations throughout the
tumour volume, (ii) a short in vivo half life of the
drug, (iii) a smaller difference in the toxicity of the
drug for hypoxic vs. aerobic KHT cells, or (iv) less
severe hypoxia in vivo.
Although the present results suggest major
differences between RSU-1069 and misonidazole
regarding the concentrations required to achieve
given levels of toxicity in aerobic and hypoxic cells,
they cast little light on the molecular mechanisms
responsible. However, it can be speculated that
these concentration differences may arise from the
fact that reduced RSU-1069 may be acting in a
bifunctional manner, whereas reduced misonidazole
acts only as a monofunctional agent.
In terms of drug dose administered to the animal,
RSU-1069 is clearly more effective than
misonidazole as an adjunct to radiation treatment.
Furthermore the finding that it is much more toxic
to hypoxic cells than misonidazole, and shows a
greater differential between aerobic and hypoxic cell
cytotoxicity, implies that it might be useful in
combination with chemotherapeutic agents, parti-
cularly those which may be limited by diffusion,
e.g. adriamycin (Tannock, 1980, 1982). Initial
studies have indicated that it can potentiate the
action of melphalan in vivo (Siemann et al., 1984).
However, when given as a single dose it is much
more toxic to mice than misonidazole (Adams et
al., 1984a). Thus, although the present results,
especially those indicating the efficacy of frac-
tionated drug doses, are encouraging, more detailed
toxicological evaluation of the drug is required
before even tentative conclusions can be made
concerning the potential therapeutic role of RSU-
1069. Other analogues of the drug such as RSU
1164 which are apparently less toxic (Adams et al.,
1984b) also deserve further study.
The authors are pleased to acknowledge the technical
assistance of Ruth Croson and Bob Kuba and the
financial support of the National Cancer Institute of
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